Multidrug- and pandrug-resistant bacteria are causing a global medical challenge for treatment of respiratory infections. Inhaled bacteriophage (phage) therapy is a promising treatment option that is gaining renewed attention due to its ability to eradicate these antibiotic-resistant superbugs. We have developed powder formulations of phages with demonstrated biological and physicochemical stabilities over storage. Efficacy study showed extremely efficacious and safe properties of our novel formulations in vivo. Furthermore, we have developed phage-antibiotic combination formulations, which further enhanced the bactericidal activity in vitro and in vivo. In this presentation, I will give an overview of the key projects we have undertaken to explore novel formulation strategies of developing inhalable and stable phage aerosols for the treatment of respiratory infections.